Teleflex TFX Interventional — Net revenues

Other product segments

Similar metrics at other companies

BDXInterventional — Revenue

$1.36B+7.4%

BSXInterventional Cardiology & Vascular Therapies — Net Sales

$1.24B+10.7%

BSXInterventional Cardiology & Vascular Therapies — Net Sales

$1.16B+10.5%

BSXInterventional Oncology & Embolization — Net Sales

$268M+17.5%

BDXInterventional — Segment Cost of Products and Services Sold as a Percent of Revenues

31.6%-0.1pp

BDXInterventional — Segment Other Operating Expense (Income), net as a Percent of Revenues

0%—

Questions, answered.

What is Teleflex's interventional — net revenues?

Teleflex (TFX) reported interventional — net revenues of $204.66M in Q1 2026.

How has Teleflex's interventional — net revenues changed year-over-year?

Teleflex's interventional — net revenues increased by 104.3% year-over-year, from $100.15M to $204.66M.

What is the long-term trend for Teleflex's interventional — net revenues?

Over 4 years (2021 to 2025), Teleflex's interventional — net revenues has grown at a 9.3% compound annual growth rate (CAGR), from $427.5M to $610.38M.

What does interventional — net revenues mean?

This metric represents the total gross sales generated by the interventional medical device segment after accounting for returns, allowances, and discounts. It reflects the market demand and commercial performance of specialized products used in minimally invasive procedures, such as diagnostic and therapeutic catheters. Tracking this revenue stream provides insight into the company's competitive position and growth trajectory within the high-acuity interventional healthcare market.